论文部分内容阅读
目的探讨缬沙坦联合倍他乐克治疗慢性充血性心力衰竭的临床效果。方法选取慢性充血性心力衰竭患者43例,根据数字随机的方法分为两组。对照组22例给予常规治疗,研究组21例在常规治疗基础上加用缬沙坦联合倍他乐克治疗。比较两组治疗效果。结果治疗后,两组患者心率、收缩压、舒张压、左心室射血分数均获改善,且研究组改善情况优于对照组(P<0.05)。研究组总有效率(90.4%)高于对照组(72.7%),差异有统计学意义(P<0.05)。治疗后,对照组生活质量评分为(5.6±2.1)分,研究组为(7.8±2.0)分,研究组生活质量评分高于对照组,差异有统计学意义(P<0.05)。结论缬沙坦联合倍他乐克在慢性充血性心力衰竭治疗中具有极高的应用价值,效果显著,安全可靠。
Objective To investigate the clinical effects of valsartan and metoprolol in the treatment of chronic congestive heart failure. Methods Forty-three patients with chronic congestive heart failure were divided into two groups according to the random number method. Control group, 22 cases given conventional treatment, 21 cases in the study group on the basis of conventional treatment plus valsartan combined with Betaloc. Compare the treatment effect of two groups. Results After treatment, heart rate, systolic blood pressure, diastolic blood pressure and left ventricular ejection fraction were improved in both groups, and the improvement in the study group was better than that in the control group (P <0.05). The total effective rate (90.4%) in the study group was higher than that in the control group (72.7%), the difference was statistically significant (P <0.05). After treatment, the quality of life in the control group was (5.6 ± 2.1) points, the study group was (7.8 ± 2.0) points, the study group quality of life score was higher than the control group, the difference was statistically significant (P <0.05). Conclusion Valsartan combined with Betaloc has high value in the treatment of chronic congestive heart failure, the effect is significant, safe and reliable.